Chari Cohen, DrPH, MPH

Cohen cites past failures with risk-based hepatitis B vaccination and voices concerns about the CDC APIC vote for individual-based decision-making.

Recent advancements in hepatology highlight new medications for metabolic dysfunction and liver diseases, promising improved patient outcomes and treatment options.

Data presented at AASLD 2025 hepatitis delta patients experience significant physical and emotional challenges, emphasizing the need for holistic care approaches and screening beyond risk-based recommendations.

In this segment of our 6-part discussion on updates and unmet needs within the management of hepatitis B virus focuses on the role of advocacy and patient voice in HBV management.

In this segment of our 6-part discussion on updates and unmet needs within the management of hepatitis B virus focuses on the most pressing unmet needs in HBV for 2024.

In this segment of our 6-part discussion on updates and unmet needs within the management of hepatitis B virus focuses on updates in the therapeutic pipeline.

In this segment of our 6-part discussion on updates and unmet needs within the management of hepatitis B virus focuses on the need to improve HBV screening and vaccination.

In this segment of our 6-part discussion on updates and unmet needs within the management of hepatitis B virus focuses on how advancing understanding of HBV DNA integration is influencing care in 2024.

In this segment of our 6-part discussion on updates and unmet needs within the management of hepatitis B virus focuses on advances in the pathophysiology of hepatitis b virus for 2024.